Elagolix Racemic Mixture
It is an impurity present in Elagolix, Elagolix is a gonadotropin-releasing hormone receptor antagonist that inhibits endogenous GnRH, By administration of elagolix shows results in dose-dependent suppression of luteinizing hormone and follicle-stimulating hormone, which leads to decreased blood concentrations of the ovarian sex hormones, estradiol, and progesterone, which is used to treat moderate to severe pain in endometriosis.
Additional information on Elagolix Racemic Mixture
VE006430
N/A
C32H29F5N3NaO5
653.57
Elagolix
Sodium (R, S)-4-((2-(5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-(trifluoromethyl)benzyl)-4-methyl-2, 6-dioxo-2, 3-dihydropyrimidin-1(6H)-yl)-1-phenylethyl)amino)butanoate
N/A
Archer, D. F., Soliman, A. M., Agarwal, S. K., & Taylor, H. S. (2020). Elagolix in the treatment of endometriosis: impact beyond pain symptoms. Therapeutic Advances in Reproductive Health, 14, 263349412096451. https://doi.org/10.1177/2633494120964517 Lamb, Yvette N. “Elagolix: First Global Approval.” Drugs, vol. 78, no. 14, Sept. 2018, pp. 1501–8, https://doi.org/10.1007/s40265-018-0977-4.
Under Development
